Ligand Pharmaceuticals Incorporated (LGND) Social Stream
LIGAND PHARMACEUTICALS INC (LGND) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering LIGAND PHARMACEUTICALS INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-10 | 5 | $310 | $170 | $206.4 | $58.31 | 253.97% |
| 2022-02-18 | 5 | $310 | $180 | $209 | $58.31 | 258.43% |
| 2022-05-05 | 5 | $310 | $130 | $191.6 | $58.31 | 228.59% |
| 2022-08-09 | 4 | $310 | $130 | $195.5 | $58.31 | 235.28% |
| 2022-09-02 | 4 | $310 | $130 | $193 | $58.31 | 230.99% |
| 2022-10-25 | 4 | $175 | $130 | $147.5 | $58.31 | 152.96% |
| 2022-11-21 | 4 | $175 | $120 | $140 | $58.31 | 140.1% |
| 2022-12-14 | 4 | $135 | $85 | $117.5 | $58.31 | 101.51% |
| 2022-12-23 | 4 | $135 | $90 | $118.75 | $58.31 | 103.65% |
| 2023-02-21 | 4 | $135 | $90 | $110 | $58.31 | 88.65% |
| 2023-03-02 | 4 | $135 | $95 | $111.25 | $58.31 | 90.79% |
| 2023-05-05 | 2 | $135 | $95 | $111.75 | $58.31 | 91.65% |
| 2023-06-02 | 3 | $144 | $95 | $114 | $58.31 | 95.51% |
| 2023-08-10 | 3 | $144 | $95 | $111.5 | $58.31 | 91.22% |
| 2023-11-13 | 4 | $144 | $95 | $111.5 | $58.31 | 91.22% |
The Trend in the Analyst Price Target
Over the past 43 months, LGND's average price target has gone down $64.83.
Over the past 49 weeks, LGND's average upside potential has been 68.42%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-06-02 | 3 | 144 | 95 | 114.0 | 75.31 | 51.37% |
| 2023-07-25 | 3 | 144 | 95 | 111.5 | 67.30 | 65.68% |
| 2023-08-10 | 4 | 144 | 95 | 111.5 | 68.73 | 62.23% |
| 2023-08-10 | 3 | 144 | 95 | 111.5 | 68.73 | 62.23% |
| 2023-11-13 | 4 | 144 | 95 | 111.5 | 55.17 | 102.1% |
LGND Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 4 | 0 | 0 | 0 | 0 | 4 |
The Trend in the Broker Recommendations
Over the past 45 months, LGND's average broker recommendation rating improved by 0.25.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- LGND has a greater number of analysts covering the stock than 279.26% of all US stocks.
- In terms of how LIGAND PHARMACEUTICALS INC fares relative to stocks in the mid market cap category, note that its average analyst price target is greater than 1873.89% of that group.
- LIGAND PHARMACEUTICALS INC's upside potential (average analyst target price relative to current price) is greater than 1611.94% of stocks in the mid market cap category.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, LIGAND PHARMACEUTICALS INC's variance in analysts' estimates is lower than -659.34% of them.
Stocks similar to LIGAND PHARMACEUTICALS INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are ARWR, IMGN, and HRTX.
View All Top Stocks by Price Target
What is the outlook for LGND? Use POWR Ratings for clearer insight into price direction.